VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
November 28, 2022 08:00 ET
|
Clene Inc.
CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct...
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
November 07, 2022 08:00 ET
|
Clene Inc.
Secondary survival endpoint for the CNM-Au8® 30 mg dose investigated in the Healey ALS Platform Trial demonstrated a >90% reduction in the risk of death or death equivalent (permanently assisted...
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
October 31, 2022 08:00 ET
|
Clene Inc.
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
October 03, 2022 08:00 ET
|
Clene Inc.
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose...
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
September 30, 2022 16:12 ET
|
Clene Inc.
SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference
September 21, 2022 07:00 ET
|
Clene Inc.
Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomizationComparable survival benefits were also shown...
Clene to Present at Upcoming September Investor Conferences
August 30, 2022 07:00 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
August 15, 2022 07:00 ET
|
Clene Inc.
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT...
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
August 15, 2022 07:00 ET
|
Clene Inc.
Topline results from the Phase 2 VISIONARY-MS clinical trial with CNM-Au8® met the primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional...
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
August 12, 2022 16:01 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...